Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.
- DOI
- 10.1111/apt.70712
- Published
- 2026 Aug
- Container
- Alimentary pharmacology & therapeutics
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/apt.70712,
title = {Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.},
author = {Inada H and Toyota T and Uojima H and Iio E and Miwa T and Miuma S and Miyase S and Mizuta T and Maeda D and Nagaoka K and Narahara S and Kurano S and Tanaka K and Yoshimaru Y and Watanabe T and Iwasaki S and Hidaka H and Sugi K and Setoyama H and Shimizu M and Nakayama J and Tanaka Y},
year = {2026},
journal = {Alimentary pharmacology \& therapeutics},
doi = {10.1111/apt.70712},
url = {https://doi.org/10.1111/apt.70712}
}RIS
TY - JOUR TI - Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial. AU - Inada H AU - Toyota T AU - Uojima H AU - Iio E AU - Miwa T AU - Miuma S AU - Miyase S AU - Mizuta T AU - Maeda D AU - Nagaoka K AU - Narahara S AU - Kurano S AU - Tanaka K AU - Yoshimaru Y AU - Watanabe T AU - Iwasaki S AU - Hidaka H AU - Sugi K AU - Setoyama H AU - Shimizu M AU - Nakayama J AU - Tanaka Y PY - 2026 JO - Alimentary pharmacology & therapeutics DO - 10.1111/apt.70712 UR - https://doi.org/10.1111/apt.70712 ER -
APA
H, I., T, T., H, U., E, I., T, M., S, M., S, M., T, M., D, M., K, N., S, N., S, K., K, T., Y, Y., T, W., S, I., H, H., K, S., H, S., M, S., J, N., & Y, T. (2026). Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.. Alimentary pharmacology & therapeutics. https://doi.org/10.1111/apt.70712
Source records
- pubmed · retrieved 2026-09-26T16:42:22.913Z